Verition Fund Management
VRDN icon

Verition Fund Management’s Viridian Therapeutics VRDN Stock Holding History

Verition Fund Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-45,072
Closed -$1.4M – 3610
2025
Q4 		$1.4M Buy
45,072
+34,752
+337% +$953K 0.01% 1894
2025
Q3 		$223K Sell
10,320
-43,605
-81% -$786K ﹤0.01% 3436
2025
Q2 		$754K Buy
53,925
+36,288
+206% +$492K ﹤0.01% 2672
2025
Q1 		$238K Buy
+17,637
New +$300K ﹤0.01% 2976
2023
Q3 		– Sell
-13,300
Closed -$316K – 2709
2023
Q2 		$316K Buy
13,300
+300
+2% +$7.7K ﹤0.01% 1524
2023
Q1 		$331K Buy
+13,000
New +$417K ﹤0.01% 1459

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Verition Fund Management's VRDN Position: Q1 2026 in Review

Verition Fund Management sold out of Viridian Therapeutics (VRDN) in Q1 2026, closing a stake of 45,072 shares — an estimated $1.4M sold.

Verition Fund Management first reported a position in VRDN in Q1 2023 and held it in 6 quarters. The position peaked at $1.4M in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Verition Fund Management reported no remaining Viridian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 45,072 Viridian Therapeutics shares in Q1 2026, an estimated $1.4M.
  • Verition Fund Management first reported a position in Viridian Therapeutics in Q1 2023 and held it in 6 quarters.
  • Verition Fund Management's Viridian Therapeutics position peaked at $1.4M in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.